{"name":"American Oriental Bioengineering, Inc.","slug":"american-oriental-bioengineering-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":145099627,"revenueGrowth":-31.8,"grossMargin":30.6,"rdSpend":6246020,"netIncome":-59713030,"cash":7097098,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2012"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AOBO-001","genericName":"AOBO-001","slug":"aobo-001","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AOBO-001","genericName":"AOBO-001","slug":"aobo-001","phase":"phase_2","mechanism":"AOBO-001 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNWXFzdlMtM1VMZjVkNHNpNzc3WXhGeVNHRGcxWWljQVhDc2x1aW8zMG8zbDFDT1Y2UXVQbDhlRzNQd1BZWkhuaDZUbVUtSC1RRjRFOENpdGVIbURlek92NkFoZ0g5dVhrMy03aEI1SEpfYXJHYUlPeDZfMjdYX1pJM3E3VEpqRml0dEtuUmllSEVwdHYzTGh4MFNqWnhvZw?oc=5","date":"2021-05-26","type":"pipeline","source":"Timmerman Report","summary":"11 Asian-American Executives Shaping the Future of Biopharma - Timmerman Report","headline":"11 Asian-American Executives Shaping the Future of Biopharma","sentiment":"neutral"},{"date":"2014-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2014-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2014-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":145099627,"revenuePeriod":"2012-12-31","revenueHistory":[{"value":145099627,"period":"2012-12-31"},{"value":212690388,"period":"2011-12-31"},{"value":305944085,"period":"2010-12-31"},{"value":296150780,"period":"2009-12-31"}],"grossProfit":44357814,"grossProfitHistory":[],"rdSpend":6246020,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-59713030,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":7097098,"cashHistory":[],"totalAssets":446308924,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}